| Dr David J Cziperle, MD | |
|
2102 Harrisburg Pike, Lancaster, PA 17601-2644 | |
| (717) 544-9400 | |
| (717) 544-9401 |
| Full Name | Dr David J Cziperle |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery |
| Experience | 36 Years |
| Location | 2102 Harrisburg Pike, Lancaster, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295797900 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2086S0129X | Surgery - Vascular Surgery | MD465466 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lancaster General Hospital | Lancaster, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lancaster General Hospital | 1254240039 | 408 |
News Archive
A team of NUS researchers from the Departments of Bioengineering and Orthopaedic Surgery has developed a highly realistic three-dimensional (3-D) tumour model. As it replicates the conditions in the body, it is able to track the effectiveness and progress of drug therapy.
Lyme disease, transmitted by a bite from a tick infected by the Borrelia burgdorferi bacteria, had long been considered easy to treat, usually requiring a single doctor's visit and a few weeks of antibiotics for most people.
Low serum levels of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) are associated with Alzheimer's Disease in men, but not women, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the breast cancer drug market in Brazil will grow from $424 million in 2009 to $611 million in 2014. Factors promoting the market's growth include steady increases in the number of incident breast cancer cases, shifts toward higher-cost chemotherapy and hormonal regimens in the adjuvant setting and increases in the use of targeted therapies following novel product launches and label extensions.
BioMarin Pharmaceutical Inc. announced today an update in the Phase 2 clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of phenylketonuria (PKU). Data reported in this announcement reflect preliminary results as of July 23, 2010. Complete top-line results are expected in the fourth quarter of 2010.
› Verified 8 days ago
| Entity Name | Lancaster General Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598038804 PECOS PAC ID: 1254240039 Enrollment ID: O20120425000426 |
News Archive
A team of NUS researchers from the Departments of Bioengineering and Orthopaedic Surgery has developed a highly realistic three-dimensional (3-D) tumour model. As it replicates the conditions in the body, it is able to track the effectiveness and progress of drug therapy.
Lyme disease, transmitted by a bite from a tick infected by the Borrelia burgdorferi bacteria, had long been considered easy to treat, usually requiring a single doctor's visit and a few weeks of antibiotics for most people.
Low serum levels of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) are associated with Alzheimer's Disease in men, but not women, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the breast cancer drug market in Brazil will grow from $424 million in 2009 to $611 million in 2014. Factors promoting the market's growth include steady increases in the number of incident breast cancer cases, shifts toward higher-cost chemotherapy and hormonal regimens in the adjuvant setting and increases in the use of targeted therapies following novel product launches and label extensions.
BioMarin Pharmaceutical Inc. announced today an update in the Phase 2 clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of phenylketonuria (PKU). Data reported in this announcement reflect preliminary results as of July 23, 2010. Complete top-line results are expected in the fourth quarter of 2010.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David J Cziperle, MD 2102 Harrisburg Pike, Lancaster, PA 17601-2644 Ph: (717) 544-9400 | Dr David J Cziperle, MD 2102 Harrisburg Pike, Lancaster, PA 17601-2644 Ph: (717) 544-9400 |
News Archive
A team of NUS researchers from the Departments of Bioengineering and Orthopaedic Surgery has developed a highly realistic three-dimensional (3-D) tumour model. As it replicates the conditions in the body, it is able to track the effectiveness and progress of drug therapy.
Lyme disease, transmitted by a bite from a tick infected by the Borrelia burgdorferi bacteria, had long been considered easy to treat, usually requiring a single doctor's visit and a few weeks of antibiotics for most people.
Low serum levels of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) are associated with Alzheimer's Disease in men, but not women, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the breast cancer drug market in Brazil will grow from $424 million in 2009 to $611 million in 2014. Factors promoting the market's growth include steady increases in the number of incident breast cancer cases, shifts toward higher-cost chemotherapy and hormonal regimens in the adjuvant setting and increases in the use of targeted therapies following novel product launches and label extensions.
BioMarin Pharmaceutical Inc. announced today an update in the Phase 2 clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of phenylketonuria (PKU). Data reported in this announcement reflect preliminary results as of July 23, 2010. Complete top-line results are expected in the fourth quarter of 2010.
› Verified 8 days ago
Mrs. Alexis Olivia Stambaugh, CRNP Surgery Medicare: Medicare Enrolled Practice Location: 2102 Harrisburg Pike, Lancaster, PA 17601 Phone: 717-544-9400 | |
Dr. George O Maish Iii, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 555 N Duke St, Lancaster, PA 17602 Phone: 717-544-5945 | |
Dr. Allison Marie Barrett, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 2135 Noll Dr Ste D, Lancaster, PA 17603 Phone: 223-202-7001 Fax: 717-312-3138 | |
Dr. Edward J Skicki Ii, DO Surgery Medicare: Accepting Medicare Assignments Practice Location: 555 N Duke St, Lancaster, PA 17602 Phone: 717-544-5945 Fax: 717-544-5944 | |
Dr. Fiona Marie Gaunay, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 2104 Harrisburg Pike Ste 200, Lancaster, PA 17601 Phone: 717-544-3626 | |
Steven L Parker, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 2104 Harrisburg Pike, Suite 200, Lancaster, PA 17601 Phone: 717-544-3626 Fax: 717-544-3628 | |
Dr. Alexander Willard Bridges, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 540 North Duke Street, Suite 110, Lancaster, PA 17602 Phone: 717-544-4995 Fax: 717-544-4944 |